Merck's lambrolizumab shows promise in advanced-melanoma trial

06/3/2013 | Reuters

Merck & Co.'s experimental drug lambrolizumab shrank tumors in 38% of advanced-melanoma patients after 12 weeks of treatment during an early-stage trial. Based on the results of the study, Merck plans to advance the drug into a late-stage trial, which could begin next quarter.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ